

knéw error®

Know Error and DNA Specimen Provenance Assignment Testing for Prostate Biopsies

DNA testing that assures patient safety and diagnostic accuracy throughout the biopsy evaluation process





The person in personalized medicine.®



The Clinical Problem

The biopsy testing cycle for cancer can involve 18 different steps¹ performed at different locations each of which creates an opportunity for a switching or contamination error. Many of the steps are outside the control of a clinician and can lead to a Specimen Provenance Complication (SPC). If undetected the result may lead to the clinician assigning a cancer diagnosis to and treating the wrong patient. Thankfully, many of these SPCs can be discovered early and corrected before iatrogenic harm befalls the patient.

DSPA Test

DNA Specimen Provenance Assignment (DSPA) testing is used to definitively assign specimen identity to the patient being evaluated. Patient misidentification, specimen transposition, and foreign cell contamination can be identified and resolved with Strand's DNA Specimen Provenance Assignment (DSPA) testing.

The DSPA process

The patient's DNA is collected via cheek swab at the clinic and sent to Strand. The biopsy tissue specimen(s) is sent to Strand from the pathology laboratory. Strand performs the DSPA test by comparing the DNA profiles of the cheek swab to the biopsy tissue specimen. A report is then issued to the physician confirming a match or nonmatch of each specimen tested.



Expect the Unknown

Data from Washington University published in the American Journal of Clinical Pathology indicate that **up to 3.5% of biopsies**² may be subject to <u>undetected</u> (occult) specimen provenance complications (SPCs) which could lead to a cancer diagnosis being assigned to the wrong patient. SPCs occurred in every urology practice and pathology laboratory evaluated in the study, concluding that **no one setting is immune from this problem** of <u>occult</u> errors.

The Prospective Solution

Strand's patented **know error® system** can detect both suspected and unsuspected (occult) specimen provenance complications. The system includes a tissue collection kit which utilizes bar coding and forensic chain of custody principles in an effort to reduce errors in the sample collection process as well as incorporating the DSPA test to confirm that the biopsy specimen diagnosis is truly matched to the patient being evaluated. When used as part of routine clinical



practice, it protects the entire diagnostic test cycle from otherwise occult errors and helps prevent adverse patient outcomes. Over 6% of prostate biopsies in U.S. are performed using the **know error® system**.

Bronner MP. DNA fingerprint analysis for specimen identification. *Clinical and Translational Pathology Research*. Div. of Pathology and Laboratory Medicine, Cleveland Clinic. 2006; Fall:5-7.
Pfeifer JD, Liu J. Rate of occult specimen provenance complications in routine clinical practice. Table 3. Am J Clin Pathol. 2013;139:93-100.



The know error® system

The **know error® system**, provided at no charge, includes a biopsy collection kit with patient identification bar codes; cheek swabs for patient DNA collection; biopsy specimen, formalin-filled containers; and microcentrifuge tubes for pathology lab submission of biopsy tissue to Strand. Once the DSPA test is complete, a report for each patient is issued to the physician confirming a match or non-match of each specimen tested. The average turn-around-time for prostate biopsy samples is 2 to 3 days.

Prostate Biopsy Kit Components



The cost of using the know error® system

Know Error collection kits are provided at no charge (including all shipping costs) along with training of medical professionals and staff. The test is run only when an ordering physician requests a DSPA test. Strand bills third-party payers for the DSPA testing and, should the non-government payer refuse to pay, the maximum out-of-pocket expense for a patient is \$295. Patients covered by a government payer will never receive a bill.

Further, in a recent study, researchers examined the costs to health care associated with the use of DSPA testing on positive samples even when no errors were suspected, that is, in routine clinical practice via the **know error® system**. The study concluded that DSPA testing is cost effective.³

DSPA testing for use with a biomarker test

When ordering tests such as OncoType[®] Dx, Prolaris[®], etc. it is important to request DSPA testing not only to confirm the test is matched to the correct patient, but that the biomarker test is performed on non-contaminated tissue. Strand has procedures in place with most biomarker companies for DSPA testing which can eliminate potential for block exhaustion.

3. Pfeifer JD, Singleton MN, et al. Development of a decision-analytic model for the application of STR-based provenance testing of transrectal prostate biopsy specimens. Value in Health. 2012; 15 (6): 860-867. OncoType Dx and Prolaris are registered trademarks of their respective owners. know error[®] is a registered trademark of Strand Diagnostics, LLC.





DNA testing that assures patient safety and diagnostic accuracy throughout the biopsy evaluation process





The **person** in personalized medicine.®



Client Services clientservices@knowerror.com 888-924-6779, option 2

5770 Decatur Boulevard Indianapolis, IN 46241 888-924-6779

www.stranddiagnostics.com www.knowerror.com



© 2014 Strand Diagnostics, LLC. All Rights Reserved. The person in personalized medicine^{*}, know error^{*} and Be DNA Certain[™] are trademarks of Strand Diagnostics, LLC. Prostate Physician Brochure 10-2014.